Home › Heart Failure › NCT06425848
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Hemodynamic Frontiers in Heart Failure Registry
Who can join
Ages 18 to 100 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. All patients would have been or will be implanted per indications from FDA approval/CHAMPION trial. These would be patients with NYHA (New York Heart Association) Class III heart failure who had a prior hospitalization. 2. Patients who meet the expanded FDA indication (BNP elevation without hospitalization or NYHA class II). Exclusion Criteria: 1. Patients less than 18 years of age. 2. Pregnant women at the scheduled time of PA pressure sensor implant. 3. Patients unable or unwilling to have continuity of care in the heart failure clinic.
About the study
The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulatory hemodynamics monitoring and HF (Heart Failure) therapies. The data collected will be used for retrospective studies, quality improvement, identifying research cohorts, and member-initiated research.
What is being tested
- Observational (device)
Sponsor: University of Kansas Medical Center · Participants: 2,000 · Started: Oct 21, 2022
Contact the study team
- Kartik Munshi, MPH · Phone: 913-945-6445
Official record on ClinicalTrials.gov — NCT06425848
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.